GeneDx Holdings Corp.· WGS
🇺🇸 US · MidBroad USNASDAQ
- Price
- $70.90
- Day
- +4.48%
- Mkt Cap
- $2.10B
- 52W Range
- $32.21 – $170.87
- Volume
- 2.66M
- Beta
- 1.98
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $0.5 per share a year ago.
Read full article
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read full article
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. If you purchased GeneDx Holdings Corp. securities during the Class Period you may be entitled to compensation without payment of any out-of-pocket fees or costs.
Read full article
New York, New York--(Newsfile Corp. - August 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the "Class Period").
Read full article
GeneDx NASDAQ: WGS reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintaining its full-year 2026 outlook.
Read full article
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (âGeneDxâ or the
Read full article
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read full article
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
Read full article
NEW YORK--(BUSINESS WIRE)---- $WGS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.
Read full article
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
Read full article
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Read full article
New York, New York--(Newsfile Corp. - August 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased GeneDx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read full article